Skip to main content
TipRanks
Go Ultimate75% OFF

Sumitomo Chemical India Ltd. (SUMICHEM) Q2 2027 Earnings Report

7 Followers

IN:SUMICHEM Q2 2027 EPS Results

Actual EPS
INR 3.20
Consensus EPS
INR 3.20
Beat/Miss
Met expectations
One Year Ago EPS
INR 3.60

IN:SUMICHEM Q2 2027 Revenue Results

Actual Revenue
INR 9.07B
Expected Revenue
INR 8.89B
Beat/Miss
Beat by +INR 180.69M
YoY Revenue Growth
-2.42%

Earnings Announcement Details

Quarter
Q2 2027
Date
10/26/2026
Time
Before Open
Conference Call
Monday, October 26, 2026
IN:SUMICHEM Upcoming Earnings

Sumitomo Chemical India Ltd.'s next earnings date is estimated for January 29, 2027, based on past reporting schedules.

Q2 2027 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2027 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2027 Earnings Call Summary

Q2 2027
Earnings Call Date:Oct 26, 2026|% Change Since:-4.58%|
Earnings Call Sentiment|Neutral

The call was cautiously balanced. SCIL maintained broadly stable H1 revenue, kept EBITDA margins above 20%, increased reported H1 net profit, generated operating cash flow, remained debt-free and advanced product, digital and CapEx initiatives. However, the operating environment was severely affected by drought-like monsoon conditions, lower volumes, weaker Q2 profitability, elevated inventory and working capital, softer exports and continued uncertainty around the semiconductor opportunity and cash deployment. Management remained cautious on the near term while expressing confidence in the company’s portfolio, pipeline and strategic direction.

Company Guidance

Management expects H2 FY 2027 to remain challenging, with El Niño expected to “peak around December” and continue through “February 2027,” reservoir levels at “about 71% of the capacity” and “at least 25% lower than the last year at the same time”; where crop area holds up and prices remain firm, consumption is expected to be “broadly normal.” The goal for H2 is to “grow our last year sales where the market allows while protecting profitability,” with margins expected to be “in the normal kind of a range as per the historical levels” and no “significant adverse” situation projected for revenues or margins; inventory is expected to come down to “normalized levels through second half.” Parent-company exports are expected to be “on the softer side” in H2, with the current-year issue expected to return to normal “next year.” The company expects to introduce “one or two new products every year” over the next “three to five years,” with commercialization taking “four or five years”; maintenance and debottlenecking CapEx has been “about INR 50 crore-INR 70 crore,” while Dahej commercial production is expected in “Q2 financial year 2028, financial year 2029.”

  • Stable H1 Revenue Despite Difficult Market ConditionsQ2 FY2027 revenue was INR 907 crore, down 2% year-on-year, while H1 revenue was INR 1,971 crore, down 1%. Management said H1 revenue was broadly in line with last year despite a clear fall in industry volumes and demand.
  • Domestic Business Demonstrated ResilienceQ2 domestic revenue grew 2% to INR 774 crore, while H1 domestic revenue was broadly stable at INR 1,657 crore. Branded products represented 79% of domestic revenue.
  • Specialty Product Portfolio Grew 22%Key specialty brands including Sumi Max, Meshi, Excalia Max, Portion, ProGibb, Nature Deep and Tribasic Copper grew in both volume and value. Together, these products grew approximately 22% in value over H1 last year despite the weak monsoon.
  • New Product Launches Expanded Innovation PortfolioSCIL launched TopGrain, a patented grain-filling biostimulant developed by Sumitomo Biorational Company, as the first commercial launch anywhere in the world, and launched Helibex insecticide on a limited basis from August. TopGrain is being evaluated in rice and is planned for wheat during the February-March consumption period.
  • Positive Early Feedback for Excalia MaxExcalia Max, based on INDIFLIN, was described as a blockbuster product with positive farmer acceptance in the U.S., Brazil and India. The molecule grew almost 50% in India during H1 despite the challenging season.
  • Strong Digital and Farmer OutreachAn Excalia Max influencer video crossed 1.7 million views, while the Sumi Max campaign won the Gen AI-led creative award at ad:tech India. The company runs more than 1,000 digital campaigns annually and reaches more than 17 million digital touchpoints.
  • H1 EBITDA Margin Remained Above 20% ObjectiveH1 gross margin was 39.9% versus 40.4% last year, while EBITDA margin was 21.3% versus 22.0% last year. Management said this was broadly in line with historical levels and its objective of maintaining EBITDA margins at or above 20%.
  • Profitability and Earnings Increased for H1Including INR 26.9 crore of exceptional income from an insurance claim related to the FY2023 Bhavnagar plant fire, H1 profit before tax increased 4% to INR 498 crore and net profit increased 5% to INR 372 crore. EPS rose to INR 7.45 from INR 7.13, and net profit margin improved by 96 basis points to 18.9%.
  • Balance Sheet Remained Debt-Free with Strong LiquidityThe company remained essentially debt-free. Cash, cash equivalents and liquid investments were approximately INR 2,523 crore as of September 30, 2026, up from INR 2,113 crore in March 2026.
  • Healthy Operating Cash Flow and CollectionsH1 net cash from operations was INR 414.7 crore versus INR 435 crore last year. Collections were INR 2,231 crore versus INR 2,277 crore last year, which management described as reasonable in a difficult collection environment. Trade receivables declined to INR 887 crore from INR 903 crore a year earlier.
  • Product Categories with Positive GrowthIn Q2, metal phosphides grew 13%, PGRs grew 9%, and animal nutrition and environmental health together grew 18%. For H1, metal phosphides grew 18% to INR 186 crore, while animal nutrition and environmental health grew 14% to INR 207 crore.
  • Exports Diversified Across Several RegionsAlthough Q2 exports declined, H1 exports were stable at INR 300 crore. Africa, South America, Asia and Europe each grew by 15%-19% during H1, and the share of branded products in export revenue increased to 41% from 34% last year, with the increase primarily contributed by Africa.
  • CapEx Projects Progressing as PlannedThe INR 150 crore greenfield Dahej project remains on track, with commercial production expected to start in Q2 FY2028-2029. Two Tarapur projects totaling INR 20 crore are also progressing as planned and will add three to four products; the first is expected to be completed during FY2027 and the second by the end of FY2027-2028.
  • Product Pipeline and India’s Early-Stage Testing Role StrengthenedIndia is now in the same tier as Brazil, North America, Europe and Japan for early-stage testing of Sumitomo Chemical pipeline products. Management expects to introduce one or two new products every year over the next three to five years, while actual launches may be higher when generics and combinations are included.
  • Good to Great Transformation Initiative LaunchedThe company launched its Good to Great: Transform to Secure Our Future program across five pillars: people, operational excellence, technology, data/digital/automation, and cross-functional success. Management said initiatives are being identified across functions to improve efficiency and support profitability objectives.
  • H2 Margin and Revenue Outlook Expected to Remain StableManagement expects H2 margins to be in the normal historical range and does not expect a significant adverse situation in revenue or margins based on currently available information. The company’s stated H2 goal is to grow last year’s sales where the market allows while protecting profitability.
  • Potential Glyphosate OpportunityManagement said glyphosate could see an opportunity following the Government of India’s ban on the competing molecule paraquat, subject to how the market develops and whether the season is favorable.
  • Biorationals Identified as a Long-Term Growth AreaManagement described biorationals as an important global and Indian focus area. Biorationals account for approximately 4%-5% of the business globally and in India, while the parent company’s biorational business was described as approximately a $500 million business expected to grow faster than traditional chemistries.
  • Low Sales Return Expected Despite Challenging SeasonManagement stated that SCIL generally does not have a sales-return policy and that teams ensured inventory was largely liquidated. Sales returns are expected to be minuscule and are not expected to affect the second half.

IN:SUMICHEM Earnings History

IN:SUMICHEM earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Jan 29, 20272027 (Q3)―-1.8――
Oct 26, 20262027 (Q2)3.203.203.6-11.11% (-0.40)
Jul 27, 20262027 (Q1)4.304.303.619.44% (+0.70)
May 26, 20262026 (Q4)2.202.20210.00% (+0.20)
Jan 27, 20262026 (Q3)2.201.801.80.00% (+0.00)
Oct 27, 20252026 (Q2)3.953.603.9-7.69% (-0.30)
Aug 04, 20252026 (Q1)―3.602.544.00% (+1.10)
May 26, 20252025 (Q4)2.802.002.2-9.09% (-0.20)
Jan 27, 20252025 (Q3)―1.801.163.64% (+0.70)
Oct 28, 20242025 (Q2)―3.902.934.48% (+1.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed